Host–microbiome interactions in nicotinamide mononucleotide (NMN) deamidation

Lynn‐Jee Kim,Timothy J. Chalmers,Romanthi Madawala,Greg C. Smith,Catherine Li,Abhirup Das,Eric Wing Keung Poon,Jun Wang,Simon P. Tucker,David A. Sinclair,Lake‐Ee Quek,Lindsay E. Wu
DOI: https://doi.org/10.1002/1873-3468.14698
2023-07-19
FEBS Letters
Abstract:Exogenous treatment with the nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) is presumed to elevate NAD+ levels through its direct incorporation via the canonical NAD+ recycling pathway. Here, metabolic tracing of strategically designed NMN isotopologues in vivo reveals that the gut microbiome mediates NMN deamidation and uptake into the NAD+ metabolome via the de novo pathway. The nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) is a proposed therapy for age‐related disease, whereby it is assumed that NMN is incorporated into NAD+ through the canonical recycling pathway. During oral delivery, NMN is exposed to the gut microbiome, which could modify the NAD+ metabolome through enzyme activities not present in the mammalian host. We show that orally delivered NMN can undergo deamidation and incorporation in mammalian tissue via the de novo pathway, which is reduced in animals treated with antibiotics to ablate the gut microbiome. Antibiotics increased the availability of NAD+ metabolites, suggesting the microbiome could be in competition with the host for dietary NAD+ precursors. These findings highlight new interactions between NMN and the gut microbiome.
cell biology,biochemistry & molecular biology,biophysics
What problem does this paper attempt to address?